Despite favorable results reported in rodent models, it is still unclear whether anti-inflammatory drugs, including adiponectin, NF-κB inhibitors, COX2 inhibitors, and inhibitors of chemokine C-X-C motif ligand 2 (CXCL2), can elicit significant effects against diabetic vascular complications in humans. Here, CXCL2 is linked to complication.